Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Interactions between BRCT repeats and phosphoproteins: tangled up in two.

Glover JN, Williams RS, Lee MS.

Trends Biochem Sci. 2004 Nov;29(11):579-85. Review.

PMID:
15501676
2.

Structure of a second BRCT domain identified in the nijmegen breakage syndrome protein Nbs1 and its function in an MDC1-dependent localization of Nbs1 to DNA damage sites.

Xu C, Wu L, Cui G, Botuyan MV, Chen J, Mer G.

J Mol Biol. 2008 Aug 29;381(2):361-72. doi: 10.1016/j.jmb.2008.05.087. Epub 2008 Jun 14.

3.

ACCA phosphopeptide recognition by the BRCT repeats of BRCA1.

Ray H, Moreau K, Dizin E, Callebaut I, Venezia ND.

J Mol Biol. 2006 Jun 16;359(4):973-82. Epub 2006 Apr 25.

PMID:
16698035
4.

The BRCT domain is a phospho-protein binding domain.

Yu X, Chini CC, He M, Mer G, Chen J.

Science. 2003 Oct 24;302(5645):639-42.

5.

Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure.

Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavletich NP.

Genes Dev. 2002 Mar 1;16(5):583-93.

6.

Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.

Ekblad CM, Friedler A, Veprintsev D, Weinberg RL, Itzhaki LS.

Protein Sci. 2004 Mar;13(3):617-25.

7.

MDC1 is a mediator of the mammalian DNA damage checkpoint.

Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ.

Nature. 2003 Feb 27;421(6926):961-6.

PMID:
12607005
8.

Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.

Rodriguez M, Yu X, Chen J, Songyang Z.

J Biol Chem. 2003 Dec 26;278(52):52914-8. Epub 2003 Oct 24.

9.

Boundaries and physical characterization of a new domain shared between mammalian 53BP1 and yeast Rad9 checkpoint proteins.

Alpha-Bazin B, Lorphelin A, Nozerand N, Charier G, Marchetti C, Bérenguer F, Couprie J, Gilquin B, Zinn-Justin S, Quéméneur E.

Protein Sci. 2005 Jul;14(7):1827-39.

10.
11.

Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor.

Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, Iwabuchi K, Doherty AJ.

EMBO J. 2002 Jul 15;21(14):3863-72. Erratum in: EMBO J 2002 Nov 1;21(21):5953.

12.
13.

The BRCA1 C-terminal domain: structure and function.

Huyton T, Bates PA, Zhang X, Sternberg MJ, Freemont PS.

Mutat Res. 2000 Aug 30;460(3-4):319-32.

PMID:
10946236
14.

Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.

Laufer M, Nandula SV, Modi AP, Wang S, Jasin M, Murty VV, Ludwig T, Baer R.

J Biol Chem. 2007 Nov 23;282(47):34325-33. Epub 2007 Sep 11.

15.

STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage.

Townsend PA, Cragg MS, Davidson SM, McCormick J, Barry S, Lawrence KM, Knight RA, Hubank M, Chen PL, Latchman DS, Stephanou A.

J Cell Sci. 2005 Apr 15;118(Pt 8):1629-39. Epub 2005 Mar 22. Retraction in: J Cell Sci. 2015 Mar 1;128(5):1064.

16.

Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1.

Williams RS, Green R, Glover JN.

Nat Struct Biol. 2001 Oct;8(10):838-42.

PMID:
11573086
17.

RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.

Sobhian B, Shao G, Lilli DR, Culhane AC, Moreau LA, Xia B, Livingston DM, Greenberg RA.

Science. 2007 May 25;316(5828):1198-202.

19.

BRCT repeats as phosphopeptide-binding modules involved in protein targeting.

Manke IA, Lowery DM, Nguyen A, Yaffe MB.

Science. 2003 Oct 24;302(5645):636-9.

20.

Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex.

Varma AK, Brown RS, Birrane G, Ladias JA.

Biochemistry. 2005 Aug 23;44(33):10941-6.

PMID:
16101277

Supplemental Content

Support Center